Earnings

Legend Biotech (LEGN) Stock Price Target Raised by UBS on NHL Outlook

Published on 6/3/2026

#LEGN#UBS#NHL#therapy#stock
Legend Biotech (LEGN) Stock Price Target Raised by UBS on NHL Outlook

AI Summary

Summarized by AI from the source below

UBS increased its price target for Legend Biotech (LEGN) reflecting a positive outlook on its NHL therapy development. No specific new price target was provided in the report. The adjustment signifies UBS's confidence in the market potential of LEGN's therapeutic advancements and could influence investor sentiment positively. This change might impact trading volumes as investors react to the report, indicating potential shifts in the stock's market dynamics.

Share:
Source: Read original article (opens in new tab)

Get the free market brief

Top stories and analysis, summarized. No spam, unsubscribe anytime.

Related News

Taylor Farms Iceberg Lettuce Recall in 27 States Due to Contamination
Earnings

Taylor Farms Iceberg Lettuce Recall in 27 States Due to Contamination

Jul 18

Energizer (ENR) Insider Aqua Capital Buys 100,000 Shares for $2M
Earnings

Energizer (ENR) Insider Aqua Capital Buys 100,000 Shares for $2M

Jul 18

Microsoft (MSFT) Stock Down 20%: Bank of America Sets $500 Target
Earnings

Microsoft (MSFT) Stock Down 20%: Bank of America Sets $500 Target

Jul 18

Vanguard Information Technology ETF (VGT) Up 21% Year-to-Date
Earnings

Vanguard Information Technology ETF (VGT) Up 21% Year-to-Date

Jul 18